nach oben

European Journal of Medical Research

Erschienen in:

01.12.2011 | Research

Increased levels of anti-glycan antibodies in patients with cystic fibrosis

verfasst von: TO Hirche, J Stein, H Hirche, J Hausmann, TO Wagner, F Behrens, O Schröder

Erschienen in: European Journal of Medical Research | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The prevalence of Crohn's disease (CD) is increased in patients with cystic fibrosis (CF). Anti-Saccharomyces cerevisiae antibodies (ASCA) have been suggested as a screening tool to detect CD in CF. Recently, several new anti-glycan antibodies have been reported in CD.

Materials and methods

The sera of 119 CF patients of various age groups were prospectively screened for ASCA type IgG (gASCA), anti-laminaribioside carbohydrate IgG antibodies (ALCA), anti-chitobioside carbohydrate IgA antibodies (ACCA), and anti-mannobioside carbohydrate IgG antibodies (AMCA). The frequency of these anti-glycan antibodies was then compared in patients with CD, ulcerative colitis, rheumatoid arthritis and healthy volunteers.

Results

A significant number of CF patients were positive for gASCA (51.3% [41.6-60.6]) and up to three other anti-glycan antibodies concurrently. Serum levels of anti-glycan antibodies in CF and CD were not related to parameters of inflammation. Despite the well-documented difference in clinical course between male and female CF patients no gender difference of anti-glycan antibodies was found. In contrast, there was a significant positive correlation between anti-glycan markers and age in CF patients.

Conclusions

Our findings demonstrate for the first time the increased frequency of a panel of anti-glycan antibodies in CF and provide a link between the presence of these serological biomarkers and patient's age. Anti-glycan antibody profiling may therefore become a valuable tool in the care of patients with CF.

Farrell PM: Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr 2000, 47: 79–115.PubMed

Strong TV, Boehm K, Collins FS: Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 1994, 93: 347–354. 10.1172/JCI116966PubMedCentralPubMedCrossRef

Eggermont E: Gastrointestinal manifestations in cystic fibrosis. Eur J Gastroenterol Hepatol 1996, 8: 731–738.PubMed

Wilschanski M: Patterns of gastrointestinal disease associated with mutations of CFTR. Curr Gastroenterol Rep 2008, 10: 316–323. 10.1007/s11894-008-0062-3PubMedCrossRef

Abraham C, Cho JH: Inflammatory bowel disease. N Engl J Med 2009, 361: 2066–2078. 10.1056/NEJMra0804647PubMedCentralPubMedCrossRef

Lloyd-Still JD: Crohn's disease and cystic fibrosis. Dig Dis Sci 1994, 39: 880–885. 10.1007/BF02087437PubMedCrossRef

Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96: 730–734. 10.1111/j.1572-0241.2001.03613.xPubMedCrossRef

Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99: 2235–2241. 10.1111/j.1572-0241.2004.40369.xPubMedCrossRef

Feizi T: Carbohydrate-mediated recognition systems in innate immunity. Immunol Rev 2000, 173: 79–88. 10.1034/j.1600-065X.2000.917310.xPubMedCrossRef

10.

Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al.: Antibodies against laminaribioside and chitobioside are novel serologic markers in crohn's disease. Gastroenterology 2006, 131: 366–378. 10.1053/j.gastro.2006.04.030PubMedCrossRef

11.

Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al.: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56: 1394–1403. 10.1136/gut.2006.108043PubMedCentralPubMedCrossRef

12.

Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, et al.: Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis 2008, 14: 645–651. 10.1002/ibd.20368PubMedCrossRef

13.

Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, et al.: Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005, 41: 23–26. 10.1097/01.mpg.0000166801.61708.60PubMedCrossRef

14.

Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B: Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997, 145: 794–803.PubMedCrossRef

15.

Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, et al.: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008, 103: 665–681. 10.1111/j.1572-0241.2007.01652.xPubMedCrossRef

16.

Henckaerts L, Pierik M, Joossens M, Ferrante M, Rutgeerts P, Vermeire S: Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 2007, 56: 1536–1542. 10.1136/gut.2007.125468PubMedCentralPubMedCrossRef

17.

Lachenal F, Nkana K, Nove-Josserand R, Fabien N, Durieu I: Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. Eur Respir J 2009, 34: 1079–1085. 10.1183/09031936.00006009PubMedCrossRef

18.

Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al.: Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996, 110: 1810–1819. 10.1053/gast.1996.v110.pm8964407PubMedCrossRef

19.

Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, et al.: Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol 2003, 15: 1281–1285. 10.1097/00042737-200312000-00005PubMedCrossRef

20.

Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, et al.: Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001, 7: 8–15.PubMedCrossRef

21.

Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al.: Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54: 1232–1236. 10.1136/gut.2004.060228PubMedCentralPubMedCrossRef

22.

Lindberg E, Magnusson KE, Tysk C, Järnerot G: Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowef disease. Gut 1992, 33: 909–913. 10.1136/gut.33.7.909PubMedCentralPubMedCrossRef

23.

Konrad A, Rütten C, Flogerzi B, Styner M, Göke B, Seibold F: Immune sensitization to yeast antigens in ASCA positive patients with Crohn's disease. Inflamm Bowel Dis 2004, 10: 97–105. 10.1097/00054725-200403000-00006PubMedCrossRef

24.

Seibold F, Slametschka D, Gregor M, Weber P: Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994, 107: 532–536.PubMed

25.

Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J: Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with crohn's disease. Gut 2000, 46: 58–63. 10.1136/gut.46.1.58PubMedCentralPubMedCrossRef

26.

Leclercq-Foucart J, Forget PP, Van Cutsem JL: Lactulose-rhamnose intestinal permeability in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1987, 6: 66–70. 10.1097/00005176-198701000-00012PubMedCrossRef

27.

Hsieh MC, Berry HK: Protease inhibitor and defective proteolysis in cystic fibrosis. Dig Dis Sci 1988, 33: 282–288. 10.1007/BF01535750PubMedCrossRef

28.

Slomiany A, Liau YH, Carter SR, Newman LJ, Slomiany BL: Mucus glycoprotein fatty acyltransferase in patients with cystic fibrosis: effect on the glycoprotein viscosity. Biochem Biophys Res Commun 1985, 132: 299–306. 10.1016/0006-291X(85)91022-8PubMedCrossRef

29.

Clarke LL, Gawenis LR, Bradford EM, Judd LM, Boyle KT, Simpson JE, et al.: Abnormal Paneth cell granule dissolution and compromised resistance to bacterial colonization in the intestine of CF mice. Am J Physiol Gastrointest Liver Physiol 2004, 286: G1050–1058. 10.1152/ajpgi.00393.2003PubMedCrossRef

30.

Wehkamp J, Harder J, Weichenthal M, Schwab M, Schäffeler E, Schlee M, et al.: NOD2 (CARD15) mutations in crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53: 1658–1664. 10.1136/gut.2003.032805PubMedCentralPubMedCrossRef

Titel: Increased levels of anti-glycan antibodies in patients with cystic fibrosis
verfasst von: TO Hirche
J Stein
H Hirche
J Hausmann
TO Wagner
F Behrens
O Schröder
Publikationsdatum: 01.12.2011
Verlag: BioMed Central
Erschienen in: European Journal of Medical Research / Ausgabe 9/2011
Elektronische ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-9-385

Springer Medizin

Abstract

Background

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review

Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma

TB or not TB? Difficulties in the diagnosis of tuberculosis in HIV-negative immigrants to Germany

Successful Non-Invasive treatment of stricturing fibrosing colonopathy in an adult patient

Investigation of the flexibility of bronchoscopes